CardiaCare
Wearable Therapy for Atrial Fibrillation
Company Overview
Snapshot
Founded in January 2015 by Amos Ziv and Tsahi Holand, CardiaCare operates with 11–50 employees. The company has raised $4.33M across four funding rounds from two investors. In December 2022, CardiaCare announced a licensing and distribution agreement to commercialize its digital neuromodulation wearable for non-invasive atrial fibrillation treatment.
Business overview
CardiaCare is a clinical-stage Digital Therapeutic company specializing in the non-invasive treatment of Atrial Fibrillation and other cardiac arrhythmias. The company has developed a closed-loop wearable device that provides nerve stimulation therapy with continuous monitoring and AI-based alerts. This platform enables complete remote patient management and personalized treatment, integrating knowledge from diverse disciplines to serve patients and healthcare providers in the digital healthcare and medical device sectors.
Strategic signal
In December 2022, CardiaCare announced a significant licensing and distribution agreement for its digital neuromodulation wearable. This agreement is a strong validation of the company's technology and signals a clear path towards commercialization, indicating a readiness to scale its non-invasive atrial fibrillation treatment solution in the market.
Company Intelligence Q&A
- What is CardiaCare's core focus?
- CardiaCare is a clinical-stage Digital Therapeutic company focused on developing a closed-loop wearable for non-invasive treatment of Atrial Fibrillation and other cardiac arrhythmias.
- When was CardiaCare founded and by whom?
- CardiaCare was founded in January 2015 by co-founders Amos Ziv and Tsahi Holand.
- What significant commercial agreement did CardiaCare announce?
- In December 2022, CardiaCare announced a licensing and distribution agreement to commercialize its digital neuromodulation wearable for non-invasive atrial fibrillation treatment.
- What was a recent funding event for CardiaCare?
- CardiaCare completed a Seed extension raise in July 2023 to support clinical pilot studies.
- What recognition did CardiaCare receive in 2019?
- In December 2019, CardiaCare was awarded first prize at the Innovation in Cardiovascular Interventions (ICI) Technology Parade in Tel Aviv, Israel.